3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
4
Neuroma, Acoustic
1
Neurofibromatosis 2
1
NSCLC
1
Meningioma
1
Lymphoma, Large-Cell, Anaplastic
1
Granuloma, Plasma Cell
1
Ependymoma
1
ALK-positive Advanced NSCLC
1
ALK+ Advanced NSCLC
1
Interventions
Magnetic Resonance Spectroscopy
7
lutetium Lu 177 dotatate
6
Specimen Handling
5
Bevacizumab
4
gallium Ga 68 dotatate
3
abemaciclib
3
Radiosurgery
3
Proton Therapy
3
Nivolumab
3
pembrolizumab
2
Surveys and Questionnaires
2
Sunitinib
2
Protons
2
Observation
2
ONC206
2
Ipilimumab
2
Hydroxyurea
2
Ga(III)-DOTATOC
2
Everolimus
2
Elasticity Imaging Techniques
2
CTLA-4 Antigen
2
tozuleristide
1
ribociclib
1
regorafenib
1
olaparib
1
neratinib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
capivasertib
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningioma
×
brigatinib
×
1 year
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled